Amicus Therapeutics

Amicus Therapeutics is a biotechnology company that focuses on developing innovative treatments for rare and orphan diseases, particularly genetic disorders such as Fabry disease and Pompe disease. The company was founded in 2002 and has since been a pioneer in the development of therapies based on genetically defined diseases. Their focus on chaperone-advanced replacement therapy (CHART) platform has resulted in the development of enzyme replacement therapies and pharmacological chaperones designed to target specific protein misfolding or instability. Overall, Amicus Therapeutics is dedicated to advancing precision medicine solutions for a range of rare genetic diseases.